Covid-19 Disease. Covid-19 Disease
Conditions
Interventions
Intervention 1: Intervention group: 3 doses of oral ivermectin 200 µg / kg once daily for 3 doses. Intervention 2: Control group: The patients in the control group will receive the standard treatment
Sponsors
Ministry of Health
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with diagnosis of COVID-19 disease
Exclusion criteria
Exclusion criteria: History of allergy to ivermectin, and evidence for current helminthic disease Advanced renal failure with GFR<30 Advanced liver failure Advanced malignancy Severe heart failure or active cardiac arrhythmia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient mortality. Timepoint: Within 28 days after the onset of the disease. Method of measurement: Physician report.;Transfer to ICU. Timepoint: Within 28 days after the onset of the disease. Method of measurement: Physician report.;Intubation or mechanical ventilation. Timepoint: Within 28 days after the onset of the disease. Method of measurement: Physician report. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improve clinical symptoms. Timepoint: Start treatment up to 28 days. Method of measurement: Physician report.;CRP value. Timepoint: Start treatment up to 28 days. Method of measurement: Measurements in serum.;LDH value. Timepoint: Start treatment up to 28 days. Method of measurement: Measurements in serum.;NLR value. Timepoint: Start treatment up to 28 days. Method of measurement: Measurement with CBCD. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Khalil Ansarin
Tabriz University of Medical Sciences
Outcome results
None listed